ALKS icon

Alkermes

29.65 USD
+0.15
0.51%
At close Dec 24, 4:00 PM EST
After hours
29.65
+0.00
0.00%
1 day
0.51%
5 days
-3.61%
1 month
0.99%
3 months
8.33%
6 months
20.38%
Year to date
3.60%
1 year
6.39%
5 years
39.14%
10 years
-47.20%
 

About: Alkermes PLC is a fully integrated biotechnology company that applies its proprietary technologies to research, develop, and commercialize pharmaceutical products designed for unmet medical needs in therapeutic areas. The company utilizes several to develop and commercialize products and, in so doing, access technological, financial, marketing, manufacturing, and other resources. Alkermes either purchases active drug products from third parties or receives them from its third-party licensees to formulate products using its technologies. It operates in U.S., which derives maximum revenue, Ireland and Rest of the world.

Employees: 2,100

0
Funds holding %
of 6,809 funds
0
Analysts bullish %
of 7 analysts

Fund manager confidence

Based on 2024 Q3 regulatory filings by fund managers ($100M+ AUM)

200% more funds holding in top 10

Funds holding in top 10: 1 [Q2] → 3 (+2) [Q3]

109% more call options, than puts

Call options by funds: $4.6M | Put options by funds: $2.2M

33% more first-time investments, than exits

New positions opened: 57 | Existing positions closed: 43

13% more capital invested

Capital invested by funds: $4.37B [Q2] → $4.94B (+$573M) [Q3]

4% more funds holding

Funds holding: 320 [Q2] → 334 (+14) [Q3]

1% more repeat investments, than reductions

Existing positions increased: 118 | Existing positions reduced: 117

2.82% less ownership

Funds ownership: 107.22% [Q2] → 104.4% (-2.82%) [Q3]

Research analyst outlook

7 Wall Street Analysts provided 1 year price targets over the past 3 months

Low target
$26
12%
downside
Avg. target
$36
20%
upside
High target
$43
45%
upside

7 analyst ratings

positive
71%
neutral
29%
negative
0%
Mizuho
Uy Ear
50% 1-year accuracy
6 / 12 met price target
35%upside
$40
Outperform
Maintained
13 Nov 2024
Stifel
Paul Matteis
13% 1-year accuracy
2 / 15 met price target
21%upside
$36
Buy
Upgraded
5 Nov 2024
Goldman Sachs
Chris Shibutani
36% 1-year accuracy
4 / 11 met price target
1%upside
$30
Buy
Maintained
25 Oct 2024
Cantor Fitzgerald
Charles Duncan
39% 1-year accuracy
32 / 82 met price target
45%upside
$43
Overweight
Maintained
25 Oct 2024
JP Morgan
Jessica Fye
39% 1-year accuracy
16 / 41 met price target
12%downside
$26
Neutral
Maintained
25 Oct 2024

Financial journalist opinion

Neutral
PRNewsWire
4 weeks ago
Alkermes to Participate in Upcoming Investor Conferences
DUBLIN , Nov. 25, 2024 /PRNewswire/ -- Alkermes plc (Nasdaq: ALKS) announced today that management will participate in two upcoming investor conferences. 7th Annual Evercore ISI HealthCONx Conference Date/Time: Tuesday, Dec. 3, 2024 at 10:25 a.m.
Alkermes to Participate in Upcoming Investor Conferences
Positive
Seeking Alpha
1 month ago
Alkermes: Products Sales, ALKS 2680 Can Still Drive Long-Term Growth
Alkermes has shifted from royalty-based revenues to proprietary product sales, driven by strong growth in Lybalvi, Vivitrol, and Aristada. ALKS 2680, a Phase 2 orexin-2 receptor agonist for narcolepsy and hypersomnia, represents a transformative opportunity in a $7.3 billion market by 2032. With $908.9 million in liquidity and a positive cash flow of $73.3 million in Q3, Alkermes can effectively fund R&D and operations.
Alkermes: Products Sales, ALKS 2680 Can Still Drive Long-Term Growth
Neutral
PRNewsWire
1 month ago
Alkermes to Participate in Two Upcoming Investor Conferences
DUBLIN , Nov. 11, 2024 /PRNewswire/ -- Alkermes plc (Nasdaq: ALKS) announced today that management will participate at two upcoming investor conferences. Stifel Healthcare Conference Date/Time: Monday, Nov. 18, 2024 at 8:35 a.m.
Alkermes to Participate in Two Upcoming Investor Conferences
Neutral
PRNewsWire
1 month ago
Alkermes Highlights Presentations From Across Neuroscience Portfolio at Key Fall 2024 Scientific Conferences
– 12 Poster Presentations Showcase Research in Schizophrenia, Bipolar I Disorder and Narcolepsy – – Results Presented From Real-World Retrospective Study of Healthcare Resource Utilization and Treatment Patterns in Patients With Schizophrenia or Bipolar I Disorder Following Initiation of LYBALVI®(olanzapine and samidorphan) – DUBLIN , Nov. 7, 2024 /PRNewswire/ -- Alkermes plc  (Nasdaq: ALKS) today announced the presentation of research related to LYBALVI® (olanzapine and samidorphan) and ARISTADA® (aripiprazole lauroxil), the company's commercial products in psychiatry, and ALKS 2680, an investigational medicine in development as a once-daily treatment for narcolepsy and idiopathic hypersomnia, at two scientific conferences this fall. The two meetings—the 37th Annual Psych Congress (Psych Congress), which took place Oct. 29-Nov. 2, 2024 in Boston, and the 2024 Neuroscience Education Institute (NEI) Congress, taking place Nov. 7-10, 2024 in Colorado Springs, Colorado—represent important opportunities for Alkermes to showcase the breadth and depth of its work in neuroscience.
Alkermes Highlights Presentations From Across Neuroscience Portfolio at Key Fall 2024 Scientific Conferences
Negative
Zacks Investment Research
2 months ago
Alkermes' Q3 Earnings & Revenues Fall Shy of Estimates, Stock Down
ALKS reports weaker-than-expected third-quarter 2024 results. Net sales of proprietary products increase year over year.
Alkermes' Q3 Earnings & Revenues Fall Shy of Estimates, Stock Down
Neutral
Seeking Alpha
2 months ago
Alkermes plc (ALKS) Q3 2024 Earnings Call Transcript
Alkermes plc (NASDAQ:ALKS ) Q3 2024 Earnings Conference Call October 24, 2024 8:00 AM ET Company Participants Sandra Coombs - Senior Vice President of Investor Relations and Corporate Affairs Richard Pops - CEO Todd Nichols - Chief Commercial Officer Blair Jackson - Chief Operating Officer. Conference Call Participants Joseph Thome - TD Cowen Umer Raffat - Evercore Paul Matteis - Stifel Charles Duncan - Cantor Fitzgerald David Amsellem - Piper Sandler Joel Beatty - Baird Uy Ear - Mizuho Securities Jessica Fye - JPMorgan Jason Gerberry - Bank of America Marc Goodman - Leerink Partners Ash Fermot - UBS Douglas Tsao - H.C.
Alkermes plc (ALKS) Q3 2024 Earnings Call Transcript
Positive
Zacks Investment Research
2 months ago
Alkermes (ALKS) Reports Q3 Earnings: What Key Metrics Have to Say
The headline numbers for Alkermes (ALKS) give insight into how the company performed in the quarter ended September 2024, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.
Alkermes (ALKS) Reports Q3 Earnings: What Key Metrics Have to Say
Negative
Zacks Investment Research
2 months ago
Alkermes (ALKS) Lags Q3 Earnings and Revenue Estimates
Alkermes (ALKS) came out with quarterly earnings of $0.73 per share, missing the Zacks Consensus Estimate of $0.78 per share. This compares to earnings of $0.64 per share a year ago.
Alkermes (ALKS) Lags Q3 Earnings and Revenue Estimates
Neutral
PRNewsWire
2 months ago
Alkermes plc Reports Third Quarter 2024 Financial Results
— Third Quarter Revenues of $378.1 Million — — Net Sales of Proprietary Products Increased Approximately 18% Year-Over-Year — — GAAP Net Income from Continuing Operations of $92.8 Million and Diluted GAAP Earnings per Share from Continuing Operations of $0.56 — — Company Reiterates 2024 Financial Expectations — DUBLIN , Oct. 24, 2024 /PRNewswire/ -- Alkermes plc (Nasdaq: ALKS) today reported financial results for the third quarter of 2024. "Our third quarter financial results reflect strong year-over-year growth of our portfolio of proprietary commercial products and position us well to meet our strategic, operational and financial priorities for the year.
Alkermes plc Reports Third Quarter 2024 Financial Results
Positive
Zacks Investment Research
2 months ago
Alkermes (ALKS) Q3 Earnings on the Horizon: Analysts' Insights on Key Performance Measures
Besides Wall Street's top -and-bottom-line estimates for Alkermes (ALKS), review projections for some of its key metrics to gain a deeper understanding of how the company might have fared during the quarter ended September 2024.
Alkermes (ALKS) Q3 Earnings on the Horizon: Analysts' Insights on Key Performance Measures
Charts implemented using Lightweight Charts™